Received by email:

File: CVR Medical.News Release (April 16, 2018) (W0354816xB74B6).pdf

                          NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
                                 OR FOR DISSEMINATION IN THE UNITED STATES



   CVR Medical Announces Proposed Financing
VANCOUVER, BC / April 16, 2018 / CVR Medical Corp. CVR Medical Corp. (TSX.V:CVM)
(FRANKFURT: B3BN) (OTCQB: CRRVF) ("CVR Medical") announces that it intends to complete a
private placement financing for gross proceeds of up to $1,000,000 (the "Financing"), which is expected
to consist of units, with each unit comprised of one common share and one-half of one common share
purchase warrant at a price of $0.40 per unit, or such other price per unit determined by CVR Medical
management in compliance with TSX Venture Exchange (the "Exchange") pricing regulations. Each
whole share purchase warrant will be exercisable to acquire one common share of CVR Medical at a price
of $0.70 per share for a period of twelve months following the closing of the Financing.

The Financing is non-brokered. CVR Medical intends to pay finder's fees of up to 6% in cash and 6% in
warrants in connection with the Financing. Proceeds from the Financing are expected to be used for
ongoing working capital requirements relating to the Joint Venture described below, specifically in regards
to FDA applications and clinical trials.

Completion of the Financing is subject to Exchange acceptance, and all securities issued pursuant to the
Financing will be subject to a hold period of four months as required under applicable securities legislation.
The securities referred to herein will not be or have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements.

For additional information on the organization, leadership, and current news please visit the company
website at www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint
Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a
proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a
diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a
proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:
Peter Bakema
CEO, President and Director

For further information contact:

Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888




This press release contains forward-looking information that involves various risks and uncertainties regarding future
---> events
related to the Joint Venture and the proposed Financing. Such statements are subject to risks and uncertainties that m
--->ay cause
                             NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
                                   OR FOR DISSEMINATION IN THE UNITED STATES

actual results, performance or developments to differ materially from those contained in the statements and are not gu
--->arantees of
future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking
---> statements
will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements ref
--->lect
management's current views and are based on certain expectations, estimates and assumptions which may prove to be inco
--->rrect.
A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implie
--->d by the
forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationa
--->lly, (2)
the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of 
--->medicine,
(3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and
development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business pla
--->n, (6) inability
to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's co
--->ntrol. These
forward-looking statements are made as of the date of this news release and, except as required by law, the Company as
--->sumes no
obligation to update these forward-looking statements, or to update the reasons why actual results differed from those
---> projected
in the forward-looking statements.


THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE
CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS
RELEASE.